Examining the Usage of Dopamine Blockers in OCD Patients

This study has been completed.

Sponsor:

Information provided by:

Sheba Medical Center

ClinicalTrials.gov Identifier:

NCT00496925

First received: July 4, 2007

Last updated: January 31, 2010

Last verified: January 2010

History of Changes

Purpose

We examine the usage of Dopamine blockers in OCD patients. We want to examine their frequency of usage, compare the course of the disease between those who receive and those who do not receive Dopamine blockers, and efficacy of the treatment.

The study will be done in two stages: 1. Collecting information the usage of Dopamine blockers from 150 OCD patients' files. 2. interviewing 60-70 patients to see the difference those who receive and those who do not receive Dopamine blockers in their current severity of disease.

Condition
Obsessive Compulsive Disorder


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Cross-Sectional
Official Title:	Examining the Usage of Dopamine Blockers in OCD Patients

Resource links provided by NLM:

Drug Information available for: Dopamine Dopamine hydrochloride

U.S. FDA Resources

Further study details as provided by Sheba Medical Center:


Enrollment:	63
Study Start Date:	November 2007
Study Completion Date:	July 2009
Primary Completion Date:	July 2009 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Outpatient and Inpatients

Criteria

Inclusion Criteria:

Patients over 18 years of age
DSM-IV diagnosis of OCD
Ability to understand patient information sheet, and consent to participate

Exclusion Criteria:

Current or past Psychotic or Bipolar disorder

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00496925

Locations


Israel
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621

Sponsors and Collaborators

Sheba Medical Center

Investigators


Principal Investigator:	Joseph Zohar, MD	Chaim Sheba Medical Center

More Information


Responsible Party:	Prof. Joseph Zohar, Chaim Sheba Medical Center
ClinicalTrials.gov Identifier:	NCT00496925 History of Changes
Other Study ID Numbers:	SHEBA- 07-4651-JZ-CTIL
Study First Received:	July 4, 2007
Last Updated:	January 31, 2010
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:


Compulsive Personality Disorder Obsessive-Compulsive Disorder Compulsive Behavior Personality Disorders Mental Disorders Anxiety Disorders Impulsive Behavior Dopamine Dopamine Antagonists	Cardiotonic Agents Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents

ClinicalTrials.gov processed this record on September 30, 2016

To Top